doi: 10.1161/hs1201.099891
(Stroke. 2001;32:2860.)
© 2001 American Heart Association, Inc.
Original Contributions |
Current Strategies of Secondary Prevention After a Cerebrovascular Event
The Vienna Stroke Registry
From the University Clinic of Neurology, Clinical Department for Clinical Neurology (W. Lalouschek, W. Lang), and University Clinic of Emergency Medicine (M.M.), University of Vienna Medical School, Vienna, Austria.
Correspondence to Professor Wolfgang Lalouschek, MD, University Clinic of Neurology, Clinical Department for Clinical Neurology, Waehringer Guertel 18-20, 1097 Vienna, Austria. E-mail wolfgang.lalouschek{at}univie.ac.at
Background and Purpose— Oral anticoagulation (OAC) and antiplatelet drugs are effective in the secondary prevention of ischemic cerebrovascular events. Only few data exist about the factors influencing the choice of a specific therapy for secondary prevention in patients with a recent stroke or transient ischemic attack (TIA).
Methods— Within a cross-sectional study, nested in a cohort we identified 931 patients with a recent ischemic stroke or TIA who were discharged with OAC or with one of the antiplatelet medications aspirin, clopidogrel, or the combination of aspirin and extended-release dipyridamole. By means of multivariate logistic regression analysis, we determined the influence of several clinical variables on the decision between OAC and overall antiplatelet therapy as well as on the decision between different antiplatelet therapies.
Results— A cardioembolic etiology of the index event and atrial fibrillation were independently associated with the use of OAC. Age was inversely associated with the use of OAC. Different estimations of contraindications to OAC were the main reason for the considerable variability among the participating centers. The most important factor promoting the use of clopidogrel was therapy with aspirin before the index event. Patients with large- or small-vessel disease received clopidogrel more often than those with an event of undetermined etiology. We found an extremely high interhospital variability for the use of the combination of aspirin with extended-release dipyridamole.
Conclusions— Current recommendations are applied in clinical practice, but great variability between different centers remains. More clearly defined guidelines for indications for, as well as contraindications against, a specific therapy are necessary.
Key Words: anticoagulants • antiplatelet agents • prevention, secondary • stroke
This article has been cited by other articles:
 |
|
 |
|
  S. Greisenegger, S. Zehetmayer, P. Bauer, G. Endler, J. Ferrari, W. Lang, M. Janisiw, L. Steiner, S. Cheng, W. Lalouschek, et al. Polymorphisms in Inflammatory Genes and the Risk of Ischemic Stroke and Transient Ischemic Attack: Results of a Multilocus Genotyping Assay Clin. Chem., January 1, 2009; 55(1): 134 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Air and B. M. Kissela Diabetes, the Metabolic Syndrome, and Ischemic Stroke: Epidemiology and possible mechanisms Diabetes Care, December 1, 2007; 30(12): 3131 - 3140. [Full Text] [PDF]
|
|
|
|
|
|
W. Lalouschek, G. Endler, M. Schillinger, K. Hsieh, W. Lang, S. Cheng, P. Bauer, O. Wagner, and C. Mannhalter Candidate Genetic Risk Factors of Stroke: Results of a Multilocus Genotyping Assay Clin. Chem., April 1, 2007; 53(4): 600 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ferrari, S. Rieger, G. Endler, S. Greisenegger, M. Funk, T. Scholze, W. Lang, W. Lalouschek, and C. Mannhalter The Thr715Pro Polymorphism of the P-Selectin Gene Is Not Associated With Ischemic Stroke Risk Stroke, February 1, 2007; 38(2): 395 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Levine, C. I. Kiefe, T. K. Houston, J. J. Allison, E. P. McCarthy, and J. Z. Ayanian Younger Stroke Survivors Have Reduced Access to Physician Care and Medications: National Health Interview Survey From Years 1998 to 2002 Arch Neurol, January 1, 2007; 64(1): 37 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Lalouschek, M. Schillinger, K. Hsieh, G. Endler, S. Tentschert, W. Lang, S. Cheng, and C. Mannhalter Matched Case-Control Study on Factor V Leiden and the Prothrombin G20210A Mutation in Patients With Ischemic Stroke/Transient Ischemic Attack Up to the Age of 60 Years Stroke, July 1, 2005; 36(7): 1405 - 1409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hsieh, W. Lalouschek, M. Schillinger, G. Endler, M. Reisinger, M. Janisiw, W. Lang, S. Cheng, O. Wagner, and C. Mannhalter Impact of {alpha}ENaC Polymorphisms on the Risk of Ischemic Cerebrovascular Events: A Multicenter Case-Control Study Clin. Chem., June 1, 2005; 51(6): 952 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Sacco, J. Sivenius, and H.-C. Diener Efficacy of Aspirin Plus Extended-Release Dipyridamole in Preventing Recurrent Stroke in High-Risk Populations Arch Neurol, March 1, 2005; 62(3): 403 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tentschert, R. Wimmer, S. Greisenegger, W. Lang, and W. Lalouschek Headache at Stroke Onset in 2196 Patients With Ischemic Stroke or Transient Ischemic Attack Stroke, February 1, 2005; 36(2): e1 - e3. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Steger, A. Pratter, M. Martinek-Bregel, M. Avanzini, A. Valentin, J. Slany, and C. Stollberger Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry Eur. Heart J., October 1, 2004; 25(19): 1734 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Greisenegger, G. Endler, K. Hsieh, S. Tentschert, C. Mannhalter, and W. Lalouschek Is Elevated Mean Platelet Volume Associated With a Worse Outcome in Patients With Acute Ischemic Cerebrovascular Events? Stroke, July 1, 2004; 35(7): 1688 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Lalouschek, W. Lang, S. Greisenegger, and M. Mullner Determination of Lipid Profiles and Use of Statins in Patients With Ischemic Stroke or Transient Ischemic Attack Stroke, January 1, 2003; 34(1): 105 - 110. [Abstract] [Full Text] [PDF]
|
|